Editorial Article
The LAM Pipeline Runs on Borrowed Placebos
<h2>The one the field quotes most is the one with no control arm</h2>
<p>Lymphangioleiomyomatosis is a rare, progressive lung disease that affects women, in which atypical cells proliferate through the lungs and destroy function. It has one drug that works. That drug, sirolimus, is off patent, and the registered clinical programme I could trace for the disease comes down to three studies — one placebo-controlled trial run by an academic network, one 24-patient exploratory study run by a large company that stopped in 2012 and has not returned, and one durability study that is still running and is funded by a patient foundation and a government institute.</p>
<p>If you want to understand why some rare-disease pipelines are full and this one is empty, the answer is not the biology. The mTOR pathway is one of the best-characterised targets in medicine. The answer is that a generic drug in a very small population has no sponsor, and the trials that fill the gap have to be designed around what someone will pay for.</p>
<h2>The single most revealing sentence in the whole literature</h2>
<p>Novartis ran NCT01059318: an exploratory, open-label, non-randomised, within-patient multiple dose-escalation trial of everolimus (RAD001) in LAM. Phase 2. Twenty-four patients. Starting dose 2.5 mg/day for four weeks, then 5 mg/day for four weeks, then 10 mg/day for eighteen weeks — a 26-week treatment period, followed by an optional extension during which patients continued until the last patient had completed 26 weeks. The longest any patient participated was 62 weeks. It started in January 2010 and completed in June 2012.</p>
<p>It had no placebo arm. The trial documentation says so plainly, and then says what it did instead: change from baseline in FVC and FEV1 was compared against historical placebo data from the multicentre trial of sirolimus in LAM (MILES, NCT00414648), and 43 patients from that trial’s placebo arm were “down weighted to an effective sample size of 18”.</p>
<p>That is a discount factor of 2.39 — 43 patients treated as though they were 18 — applied because “of absence of placebo group in this current study on a rare lung disease.” Two studies with different designs had to be stapled together, and the borrowed patients had to be devalued to make the comparison honest.</p>
<p>Everything about the LAM pipeline is in that manoeuvre. The expensive part of a rare-disease trial is not the drug, it is the control arm, and the field could not afford one.</p>
<h2>What an actual approval looked like</h2>
<p>Japan is the only jurisdiction where I have been able to verify a labelled indication for LAM, and the record of how it got there is instructive. Nobelpharma Co., Ltd. applied on 21 October 2013. The PMDA’s review report is dated 15 May 2014, the Second Committee on New Drugs concluded on 26 May 2014 that the product may be approved, and the deliberation results were reported on 10 June 2014. The product is Rapalimus Tablets 1 mg. The orphan designation is number [24 yaku] No. 286, notified 13 September 2012 — which means the orphan route was the route, from the start.</p>
<p>Now read the conditions attached to the approval, because they are the economics of the category written as regulation:</p>
<ul>
<li>A <strong>10-year re-examination period</strong>.</li>
<li>The applicant must conduct a <strong>drug use-results survey in all patients</strong> until data from a certain number of patients have been accumulated, “because there are extremely few Japanese patients who have been treated with the drug.”</li>
<li>An <strong>all-case post-marketing surveillance</strong> obligation, because the product “was evaluated in an extremely limited number of patients with LAM in both Japanese and foreign clinical studies”, and because serious adverse events including interstitial lung disease and serious infectious disease may occur.</li>
</ul>
<p>The regulator approved the drug while stating in writing that the evidence base was extremely limited, and then made total post-market capture a condition of keeping it. Those two things are the same fact. When you cannot run a large trial, you replace the trial with a census — and a census is a permanent, unbudgeted operating cost that no commercial sponsor would accept for a molecule it cannot price.</p>
<p>Which is precisely why the applicant was Nobelpharma, a company whose business is orphan drugs that nobody else will take on, and not the originator of sirolimus.</p>
<h2>The name on the file that tells you who funds the field</h2>
<p>The third study is MIDAS — the Multicenter International Durability and Safety of Sirolimus in LAM Trial, NCT02432560. Sponsor: the University of Cincinnati. Collaborators: the Rare Diseases Clinical Research Network, the National Institutes of Health, the National Heart, Lung, and Blood Institute, and The LAM Foundation. It began in March 2015 and its primary completion date was 31 July 2025.</p>
<p>That collaborator list is the pipeline. Not a company, not a licensing deal, not a platform — a university, a public research network, a public institute and a patient foundation. And the question MIDAS exists to answer is not “does sirolimus work”; MILES answered that. It is “does it keep working” — durability across years, in men as well as women, with the safety profile characterised over a long horizon.</p>
<p>A decade-long, publicly funded durability study is what a phase 4 looks like when there is no marketing department to pay for one.</p>
<h2>The real bottleneck is the endpoint, not the molecule</h2>
<p>Here is the part that is least discussed and most decisive. LAM’s progression is measured by the slope of forced expiratory volume — a slow decline, in a small and heterogeneous population, over a period long enough for the measurement noise to swamp the treatment effect. To detect a difference in slope you need cohort size, and cohort size in a disease this rare means multi-country recruitment over years.</p>
<p>That is why the everolimus study used an FVC change against a discounted historical control rather than a powered randomised comparison. It is why the field’s registrational evidence is retrospective in structure even where it is prospective in conduct. And it is why a new entrant with a genuinely better molecule would still face the same cost: the trial that would prove superiority costs the same as the trial that proved equivalence, and the population to recruit from has not grown.</p>
<p>The only way out of that trap is an endpoint that moves faster or a biomarker that predicts. The rare-biomarker and specimen-collection infrastructure that has grown up around rare disease is, in this light, not an ancillary service — it is the enabling condition for the next LAM trial.</p>
<h2>Where I am refusing a number</h2>
<p>This article gives no market size for LAM, and the reason is not modesty. A disease with one generic drug, one verified labelled indication, and a treated population that the regulator itself describes as “extremely few” has no price, no volume series and no enumerated patient count in any public source I could reach. Any figure would be an assumption dressed as a measurement.</p>
<p>I also will not read across the broader rare-disease or mTOR markets and present a share of them. The mechanism is shared with oncology and transplant medicine; the indication is not; and the pricing logic in an ultra-rare lung disease with an off-patent active bears no relation to either.</p>
<h2>The point</h2>
<p>The LAM pipeline is not thin because the science failed. It is thin because the science succeeded, cheaply, with a drug that went generic — and a generic cannot fund a control arm. So the field borrowed 43 patients from an academic trial, discounted them to 18, and submitted the result. Ten years later it is still asking whether the drug keeps working, with the bill paid by a foundation and a public institute. That is what a functioning pipeline looks like when there is no one to sell it to.</p>
Frequently Asked Questions
Is there an approved treatment for LAM?
The only labelled indication I could verify is Japan's. Sirolimus was approved there as Rapalimus Tablets 1 mg for Nobelpharma Co., Ltd., following an orphan designation notified on 13 September 2012, an application on 21 October 2013, and a PMDA review reported in 2014. The approval carried a 10-year re-examination period and all-case post-marketing surveillance.
Why did the everolimus LAM trial have no placebo group?
Because the field could not fund a control arm in a disease this rare. Trial NCT01059318 compared change from baseline in lung function against historical placebo data from the MILES trial, down-weighting 43 placebo patients to an effective sample size of 18 — a discount factor of 2.39 — because the current study had no placebo group.
What is the MIDAS trial?
The Multicenter International Durability and Safety of Sirolimus in LAM Trial, NCT02432560, sponsored by the University of Cincinnati with the Rare Diseases Clinical Research Network, the US National Institutes of Health, the National Heart, Lung, and Blood Institute and The LAM Foundation. It began in March 2015 with a primary completion date of 31 July 2025.
Why is there no larger LAM drug pipeline?
The drug that works is off patent and the patient population is very small, so no commercial sponsor can recover the cost of a registrational trial from it. The result is that the field's trials are investigator-initiated and funded by public institutes and a patient foundation, and the regulator replaces the missing trial evidence with all-case post-marketing surveillance.